FEATURED

CTOS 2018 Coverage

Follow our coverage of the Connective Tissue Oncology Society 2018 meeting in Rome, Italy.

Trials, Collaboration and Survival Disparities

Better collaboration between community and academic cancer centers could benefit patients.

Outcome Prediction for DLBCL

The model was developed using machine learning techniques and programmed with data from a Danish cancer registry.

Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Ask the Experts: NSCLC

Cancer Therapy Advisor asked 2 experts to weigh in on recommended treatment modalities for patients with non-small cell lung cancer.

Ask the Experts: STS Clinical Insights

Cancer Therapy Advisor asked 2 experts to weigh in on the latest clinical insights into soft tissue sarcoma.

Ask the Experts: Waldenström Macroglobulinemia

Cancer Therapy Advisor asked 3 experts to weigh in on recommended treatment modalities for patients with Waldenström macroglobulinemia.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Latest Features

Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers

Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers

Better collaboration between community and academic cancer centers could benefit patients.

New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma

New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma

The model was developed using machine learning techniques and programmed with data from a Danish cancer registry.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

The majority of patients studied who stopped TKI therapy remained treatment-free at 3 years.

Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

In the immunotherapy era, the optimal setting and sequencing of BRAF+MEK inhibition remains unresolved.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs